Skip to main content
HAE
NYSE Industrial Applications And Services

Haemonetics Lifts FY27 Revenue Guidance to 8-11% on 10% Organic Q2 Growth

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Instrument Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$127.42
Mkt Cap
$5.797B
52W Low
$49.96
52W High
$128.825
52W Position info
155% above low
Off High info
1.1% below high
Rel. Volume info
1.4× avg
Market data snapshot near publication time

HAE has more than doubled off its 52-week low of $49.96.

Summary

Haemonetics posted 9.3% Q2 revenue growth to $357.8M with 10% organic growth and raised FY27 revenue guidance to 8-11%, while cutting margin expansion guidance to 0-50 bps.


Key Events · Earnings and Guidance · HAE

  • Q2 Revenue Up 9.3% to $357.8M

    Organic growth was 10.0%, led by Apheresis at 13.6% organic and Plasma at 17.7% organic; MedSurg grew 5.5% organically.

  • FY27 Revenue Guidance Raised

    Reported revenue guidance moves to 8-11% from 5-8% and organic to 6-9% from 4-7%, with Apheresis now expected high-single-digit versus low-to-mid-single-digit before.

  • Margin Guidance Trimmed

    Adjusted operating margin expansion guidance was cut to 0-50 bps YoY from 50-100 bps, even as Q2 adjusted operating margin was 26.3%, down 40 bps year over year.

  • Cash Generation Strengthens

    Q2 operating cash flow was $128.1M and free cash flow $103.8M, up $15.1M YoY; cash on hand rose to $260.7M and long-term debt fell to $1.11B from $1.22B.


Analysis · HAE · Industrial Applications And Services

Haemonetics outpaced its own prior revenue trajectory: Q2 revenue rose 9.3% to $357.8M and organic growth reached 10.0%, powered by Plasma up 17.7% organically as the CSL rollout ramps. Management raised full-year reported revenue guidance to 8-11% from 5-8% and organic to 6-9% from 4-7%, but trimmed margin expansion to 0-50 bps from 50-100 bps — growth is coming at a cost. Adjusted EPS of $1.35 was up 6.3%, and free cash flow conversion guidance improved to >80%. With the stock near its 52-week high, the guidance mix (more revenue, less margin) is the number that decides whether that holds.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, HAE was trading at $127.42 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $5.8B. The 52-week trading range was $49.96 to $128.83. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

HAE - Latest Insights

HAE
Nov 05, 2026, 6:13 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $127.42
Real-time Price: $120.16 info
Change: -$7.26 (-6%) info
Market Cap: $5.472B info
HAE
Oct 19, 2026, 4:15 PM EDT
Source: PR Newswire
Importance Score:
7
Price at Filing: $118.73
Real-time Price: $120.16 info
Change: +$1.43 (+1%) info
Market Cap: $5.472B info
HAE
Oct 08, 2026, 3:50 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $101.71
Real-time Price: $120.16 info
Change: +$18.45 (+18%) info
Market Cap: $5.472B info
HAE
Aug 18, 2026, 6:03 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $96.06
Real-time Price: $120.16 info
Change: +$24.10 (+25%) info
Market Cap: $5.472B info
HAE
Aug 06, 2026, 6:07 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $83.50
Real-time Price: $120.16 info
Change: +$36.66 (+44%) info
Market Cap: $5.472B info